Dermatology Collaboration and Licensing Deals 2016-2025 | Unprecedented Access to Biopharma Licensing Terms - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Dermatology Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

Fully revised and updated, the report provides details of 474 dermatology deals from 2016 to 2025.

Dermatology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the dermatology deals entered into by the world's leading biopharma companies.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of dermatology dealmaking and business activities. Chapter 1 introduces the report, while Chapter 2 analyzes trends in dermatology dealmaking. Chapter 3 highlights financial deal terms specific to the dermatology field, listing them by headline value, upfront payment, milestone payment, and royalty rates. Chapter 4 discusses the top 25 biopharma companies actively engaging in dermatology dealmaking, offering links to SEC-published contract agreements. Chapter 5 details dermatology deals with available contract documents, and Chapter 6 organizes dermatology deals by therapeutic target, accessible through web links.

The report also includes numerous table and figures that illustrate the trends and activities in dermatology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Dermatology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse dermatology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in dermatology dealmaking

2.1. Introduction

2.2. Dermatology partnering over the years

2.3. Dermatology partnering by deal type

2.4. Dermatology partnering by industry sector

2.5. Dermatology partnering by stage of development

2.6. Dermatology partnering by technology type

2.7. Dermatology partnering by therapeutic indication

Chapter 3 - Financial deal terms for dermatology partnering

3.1. Introduction

3.2. Disclosed financials terms for dermatology partnering

3.3. Dermatology partnering headline values

3.4. Dermatology deal upfront payments

3.5. Dermatology deal milestone payments

3.6. Dermatology royalty rates

Chapter 4 - Leading dermatology deals and dealmakers

4.1. Introduction

4.2. Most active in dermatology partnering

4.3. List of most active dealmakers in dermatology

4.4. Top dermatology deals by value

Chapter 5 - Dermatology contract document directory

5.1. Introduction

5.2. Dermatology partnering deals where contract document available

Chapter 6 - Dermatology dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by dermatology therapeutic target

Deal directory

Deal directory - Dermatology deals by company A-Z 2016 to 2025

Deal directory - Dermatology deals by technology type 2016 to 2025

Deal type definitions

Companies Featured

• 3M
• Abbvie
• Adaptive Phage Therapeutics
• Advanz Pharma
• AFT Pharmaceuticals
• AiCuris
• Almirall
• Amgen
• Amicus Therapeutics
• Amor (Suzhou) Medical Sci-Tech
• Antibe Therapeutics
• AOBiome Therapeutics
• APR Applied Pharma Research
• AstraZeneca
• Avicanna
• Azitra
• BASF
• Beiersdorf
• Biocon
• BioCryst Pharmaceuticals
• Biogen
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene
• Chugai Pharmaceutical
• Cipla
• ConvaTec
• Dabur
• Dr. Reddy's Laboratories
• Eli Lilly
• Gilead Sciences
• GSK
• Johnson & Johnson
• Leti Pharma
• Mallinckrodt Pharmaceuticals
• MedPharm
• Mitsubishi Tanabe Pharma
• Mylan Pharmaceuticals
• Novartis
• Novo Nordisk
• Pfizer
• Perrigo
• Roche
• Sanofi
• Sandoz
• Sun Pharmaceutical
• Teva Pharmaceutical Industries
• Valeant Pharmaceuticals
• Verrica Pharmaceuticals
• Zentiva

For more information about this report visit https://www.researchandmarkets.com/r/8wpghj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.